Project Grant R44CA295318
Award Date 9/2/25
Completion Date 8/31/27
Dollars Obligated $882K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $285,599 Project Grant to Sinopia Biosciences Inc., a San Diego-based company specializing in computational drug discovery and metabolomics research. The grant will support the development of a metabolomics-enabled AI/ML platform for identifying new treatments to enhance drug sensitivity in cancer. The project aims to leverage high-throughput omics technologies, machine learning, and a chemical library of ~3,300...
- The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $670,534 Project Grant to Northwestern University to develop an optical hyperspectral nanoscale chromatin analysis technology for colorectal cancer risk stratification. The goal is to create a screening test to identify patients who harbor advanced adenomas and should undergo colonoscopy, with a target of 99.5% negative predictive value, 95% sensitivity, and 80% specificity for advanced adenomas....
- The National Cancer Institute (NCI) awarded a $399,816 Project Grant to Xgenomes Corp., a minority-owned biotechnology company in Cambridge, MA, under the Cancer Detection and Diagnosis Research (CFDA 93.394) federal grant program. The purpose of the 1-year project is to further develop Xgenomes' novel DNA analysis platform that can directly measure both genetic mutations and epigenetic methylation changes with over 100x greater accuracy than current next-generation sequencing methods. The...
- The National Cancer Institute (NCI) has awarded a $554,653 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Institute for Systems Biology (ISB) in Seattle, WA. The 4-year grant titled "RARECYTEFINDER: A BENCH-TO-BITS TOOLKIT FOR LABEL-FREE, WHOLE-SPECTRUM ANALYSIS OF RARE DISSEMINATED TUMOR CELLS IN LIQUID AND TISSUE BIOPSIES" aims to develop an innovative, unbiased method for identifying and analyzing rare disseminated tumor cells (DTCs)...
- This federal Project Grant award of $592,866 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to develop ingestible nanosensors for the early detection of colorectal cancer through breath-based biomarkers. The principal objectives are to engineer nanosensors that can sense specific enzymes associated with tumor development in the intestinal mucosa and release volatile reporters that can be detected in the patient's breath. This non-invasive...
- The National Cancer Institute (NCI) has awarded a $727,904 Cooperative Agreement to The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division, under the Cancer Biology Research program (CFDA 93.396). The purpose of this 23-month award, with a start date of August 11, 2025, is to engineer probiotic bacteria (E. coli Nissle 1917) to identify precancerous lesions, characterize novel stage-specific immune targets, and design immunomodulatory...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $1,233,778 Project Grant to Matrisome Bio, Inc. to develop an extracellular matrix-targeted theranostic radiopharmaceutical for treating metastatic lung cancer. The funding will support research and development efforts to create molecularly targeted drugs using nanobodies that specifically bind to disease-associated extracellular matrix proteins in lung tumors and metastases. This novel approach aims to...
- This $435,827 Project Grant from the National Cancer Institute (NCI) under the CFDA 93.394 Cancer Detection and Diagnosis Research program supports research conducted by New York University (NYU) School of Medicine to develop deep learning methods for analyzing mass spectrometry imaging (MSI) data. The goal is to make MSI data more accessible to existing machine learning workflows by expanding the dimensionality of the data structure to treat each metabolite or lipid as an individual "color...
- This $471,675 project grant from the Department of Health and Human Services National Institutes of Health National Cancer Institute Cancer Detection and Diagnosis Research program (CFDA 93.394) will fund research at Oregon Health & Science University to develop a nanoparticle-based blood test to distinguish pancreatic cancer from benign pancreatic disease. The researchers will use high conductance dielectrophoresis technology to simultaneously recover different types of cancer-derived...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $405,973 to Intus Biosciences LLC (DBA Shoreline Biome LLC) to develop and validate a novel non-invasive, high-throughput fecal microbiome-based screening platform for the detection of colorectal cancer (CRC) and advanced adenoma (AA) precancerous lesions. The platform, called TITAN-1, utilizes machine learning to analyze fecal samples collected at home, with the goal of...